All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

CorMedix swings to Q3 2026 net loss of $14.72 million

By Public Technologies
  • CorMedix swung to a third-quarter 2026 net loss of $14.7 million from net income of $108.6 million a year earlier.
  • Consolidated revenue fell 48% year over year to $54.5 million, with DefenCath sales declining largely due to lower post-TDAPA pricing.
  • The pending acquisition of substantially all Heron Therapeutics assets is expected to close in the first quarter of 2027.
  • Full-year 2026 consolidated revenue guidance remains $325 million to $345 million.
  • Previously issued 2027 DefenCath revenue guidance was suspended following recently announced CMS reimbursement framework changes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120730PRIMZONEFULLFEED9876110) on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.